Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Sarepta Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 25, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their achievements in recovering hundreds of millions of dollars for investors [4]. - The firm has been recognized for its performance in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4]. Group 3: Case Allegations - The lawsuit alleges that Sarepta made false and misleading statements regarding its gene therapy ELEVIDYS, which posed significant safety risks and failed to detect severe side effects during trials [5]. - It is claimed that the adverse events from ELEVIDYS treatment led to a halt in recruitment and dosing in trials, attracting regulatory scrutiny and increasing risks around the therapy's approvals [5].

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and certain senior executives for potential violations of federal securities laws, particularly concerning the safety claims of their product Elevidys [1][2]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [3]. Allegations and Claims - The lawsuit alleges that Sarepta misrepresented the safety profile of Elevidys, claiming that the benefits outweighed the risks, while in reality, the treatment has been linked to fatal acute liver failure in some patients [3]. Stock Performance and Market Reaction - Following the announcement of a patient's death due to acute liver failure after receiving Elevidys, Sarepta's stock price dropped by $27.81, or over 27%, from $101.35 on March 17, 2025, to $73.54 on March 18, 2025 [4]. - After a second patient death was reported on June 15, 2025, the stock fell by $15.24, or more than 42%, from $36.18 on June 13, 2025, to $20.94 on June 16, 2025 [4]. - A third patient death related to Elevidys was disclosed on July 17, 2025, leading to a further decline of over 40% in the stock price on July 18, 2025 [5]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Southern District of New York, with investors having until August 25, 2025, to seek lead plaintiff status [2].

Group 1: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - The class period for Sarepta is from June 22, 2023, to June 24, 2025, with a lead plaintiff deadline of August 25, 2025 [2] - The lawsuit alleges that Sarepta made materially false and misleading statements regarding its gene therapy ELEVIDYS, which was intended to treat Duchenne muscular dystrophy, leading investors to believe it was safe and had a positive revenue outlook [2] - Significant safety risks associated with ELEVIDYS were not disclosed, including severe side effects that led to the halting of trials and regulatory scrutiny [2][3] - Following the announcement of a patient death related to ELEVIDYS, Sarepta's stock price fell by $27.81 (27.44%) to close at $73.54 on March 18, 2025 [3] - Subsequent disclosures of additional patient deaths and regulatory investigations resulted in further stock price declines, with a notable drop of $15.24 (42.12%) to close at $20.91 on June 15, 2025 [3] Group 2: Petco Health and Wellness Company, Inc. (NASDAQ:WOOF) - The class period for Petco is from January 14, 2021, to June 5, 2025, with a lead plaintiff deadline of August 29, 2025 [4] - The lawsuit claims that Petco made materially false and misleading statements about its business operations, particularly regarding the sustainability of pandemic-related growth and the viability of its premium pet food business model [4][5] - Defendants allegedly overstated Petco's ability to achieve sustainable, profitable growth, with a specific reference to a share price of $95.85 on May 21, 2025 [5]

Core Insights - Sarepta Therapeutics announced a major restructuring involving a 36% workforce reduction, equating to 500 employees, aimed at saving approximately $400 million annually [1] - The FDA has mandated a black box warning for Sarepta's gene therapy drug, ELEVIDYS, due to risks of acute liver injury and acute liver failure [1] Legal Issues - A securities class action lawsuit has been filed against Sarepta, representing investors who acquired securities between June 22, 2023, and June 24, 2025 [2][4] - The lawsuit alleges that Sarepta misled investors regarding the safety and efficacy of ELEVIDYS, claiming the company portrayed the drug as safe while withholding critical risk information [4][5] Safety Concerns - The lawsuit highlights that Sarepta failed to disclose significant safety risks associated with ELEVIDYS and inadequacies in clinical trial protocols [5] - A timeline of events indicates that Sarepta reported a patient death during a trial on March 18, 2025, followed by further disclosures of deaths and regulatory scrutiny [6][7][8] Regulatory Scrutiny - On July 25, 2025, the European Medicines Agency rejected ELEVIDYS due to questions about its effectiveness, leading to a further decline in Sarepta's stock price [9]

Core Points - A class action securities lawsuit has been filed against Sarepta Therapeutics, Inc. for alleged securities fraud affecting investors between June 22, 2023, and June 24, 2025 [1] - The lawsuit claims that Sarepta misled investors regarding the safety and efficacy of its gene therapy product, ELEVIDYS, for Duchenne muscular dystrophy [2] Group 1 - The lawsuit seeks to recover losses for Sarepta investors who were adversely affected by the alleged fraud [1] - The complaint alleges that ELEVIDYS posed significant safety risks, and that trial protocols failed to detect severe side effects [2] - It is claimed that the severity of adverse events would lead to a halt in recruitment and dosing in ELEVIDYS trials, attracting regulatory scrutiny [2] Group 2 - Investors who suffered losses during the relevant time frame have until August 25, 2025, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] - The firm Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders [4]

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...

Core Viewpoint - Sarepta Therapeutics, Inc. has faced significant stock price decline following the reported deaths of patients in clinical trials for its gene therapy drug ELEVIDYS, leading to a securities class action lawsuit from investors [1][4][10]. Group 1: Company Developments - On July 18, 2025, Sarepta's shares closed down $7.89, a decrease of 36%, after the announcement of a third patient death related to its experimental gene therapy [1]. - The lawsuit focuses on Sarepta's disclosures regarding the safety and efficacy of ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [4]. - The FDA has placed Sarepta's investigational gene therapy clinical trials for limb-girdle muscular dystrophy on clinical hold due to the reported patient deaths [10]. Group 2: Legal Actions - A securities class action lawsuit has been filed, representing investors who acquired Sarepta securities between June 22, 2023, and June 24, 2025 [2]. - The lawsuit alleges that Sarepta made false and misleading statements about the safety of ELEVIDYS and failed to disclose critical information regarding patient deaths [5][6]. - Hagens Berman, the law firm investigating the case, is urging affected investors to report their losses and is looking for individuals with knowledge to assist in the investigation [3][11]. Group 3: Regulatory and Market Impact - Following the patient deaths, Sarepta halted recruitment and dosing in some ELEVIDYS clinical studies, which has attracted regulatory scrutiny [7][8]. - The severity of adverse events related to ELEVIDYS has raised concerns about the therapy's current and future approval prospects [8]. - H.C. Wainwright has reduced its price target for Sarepta to $0, reflecting the negative market sentiment following these developments [10].

Group 1 - China Biopharmaceutical (1177.HK) saw a rise of over 3% after announcing a successful licensing agreement with Merck for its PD-1/VEGF dual antibody, expecting a $300 million milestone payment soon [1] - CSPC Pharmaceutical Group (1093.HK) increased by over 5% following the announcement of an exclusive licensing agreement with Madrigal Pharmaceuticals for the global development of its GLP-1 receptor agonist SYH2086 [1] - Youzan (8083.HK) surged over 7% as it projected a revenue of approximately 709 to 719 million RMB for the first half of the year, a year-on-year increase of about 3.3% to 4.8%, and a net profit of 68 to 74 million RMB, marking a turnaround from a loss last year [1] Group 2 - Xingsheng International (6058.HK) rose nearly 18% after the bank announced its commitment to embrace technological transformation and explore stablecoins and AI initiatives [2] - New Oriental Education (9901.HK) fell nearly 4% after reporting a 9.4% year-on-year increase in net revenue to $1.243 billion for the fourth quarter of fiscal year 2025, but a 73.7% drop in net profit [2] - Kingdee International (0268.HK) saw a rise of over 7% as it announced a board meeting to review its interim results and potential dividend distribution [2] Group 3 - Macau gaming stocks rose, with MGM China (2282.HK) up over 4% after Macquarie raised its forecast for Macau's total gaming revenue for 2025 by 5% to 235.7 billion RMB, indicating a year-on-year growth of 4% [3] - Gold stocks in Hong Kong continued to decline, with Tongguan Gold (0340.HK) dropping over 9% for six consecutive days, as spot gold prices fell below $3,270 per ounce [4] - Kangfang Biopharma (9926.HK) rose nearly 5% after announcing the completion of the first patient dosing in a pivotal clinical trial for its PD-1/VEGF dual-specific antibody [4] Group 4 - Weishi Jiajie (0856.HK) increased by over 3% as a report indicated that its Southeast Asia business is expected to see a significant revenue increase of 74% in 2024, with net profit contributing about 51% [5] Group 5 - Meta (META.US) exceeded revenue expectations and provided strong guidance for the current quarter, leading to an after-hours increase of over 11% [6] - Microsoft (MSFT.US) reported an 18% year-on-year growth in revenue, driven by its cloud business, with Azure revenue up 34% for the full year, resulting in an after-hours increase of over 8% [6] - Wingstop (WING.US) surged by 26.85% after reporting adjusted earnings per share of $1.00 for the second quarter, exceeding analyst expectations [6] Group 6 - Several biopharmaceutical stocks surged, with Replimune (REPL.US) up 101.33% following news of regulatory changes at the FDA that may ease pressure on gene therapy and vaccine companies [7] - Marvell Technology (MRVL.US) rose 7.07% after announcing a partnership with Rebellions to provide AI systems for regional projects in Asia-Pacific and the Middle East [7] - Palo Alto Networks (PANW.US) fell 5.58% after agreeing to acquire CyberArk Software for approximately $25 billion [8]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Sarepta Therapeutics, Inc. securities between June 22, 2023, and June 24, 2025, of the upcoming lead plaintiff deadline on August 25, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Sarepta securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 25, 2025 [3]. - The lawsuit claims that Sarepta made false and misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, which led to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements since 2013 [4].

Core Viewpoint - Sarepta Therapeutics, Inc. experienced a significant decline in share price following the report of a third patient death related to its experimental gene therapy drug, ELEVIDYS, leading to a 36% drop in stock value on July 18, 2025 [1]. Group 1: Company Developments - The company reported the death of a third patient treated with ELEVIDYS, resulting in shares closing down $7.89 [1]. - A securities class action lawsuit has been filed against Sarepta, representing investors who acquired securities between June 22, 2023, and June 24, 2025 [2]. - The lawsuit focuses on Sarepta's disclosures regarding the safety and efficacy of ELEVIDYS, alleging that the company misled investors about the therapy's safety and potential for broader application [4]. Group 2: Legal and Regulatory Issues - The lawsuit claims that Sarepta made false statements and failed to disclose critical information, particularly regarding patient safety updates that began on March 18, 2025 [5]. - Following the initial death report, Sarepta halted recruitment and dosing in some clinical studies as requested by EU authorities [6]. - Subsequent deaths of patients treated with ELEVIDYS led to further regulatory scrutiny, including a safety communication from the FDA regarding acute liver failure risks [8]. Group 3: Market Reactions and Analyst Opinions - The financial press reported that following the lawsuit, H.C. Wainwright reduced its price target for Sarepta to $0, reflecting a loss of confidence in the company's future prospects [10]. - The investigation by Hagens Berman is focused on whether Sarepta misled investors about the safety and revenue potential of its gene therapies [11].